Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shenzhen Edge Medical Co., Ltd.
深圳市精鋒醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2675)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2025 ANNUAL REPORT

Reference is made to the 2025 annual report of the Company for the year ended December 31, 2025 (the "**Annual Report**"). Unless otherwise stated, capitalized terms used in this announcement shall have the same meanings as those defined in the Annual Report.

In addition to the information disclosed in the section headed "Material Acquisitions and Disposals and Significant Investments" in the Annual Report, the Board wishes to provide the Shareholders and potential investors with information in relation to the wealth management products which constituted significant investments held by the Company as at December 31, 2025 (the "**Significant Wealth Management Products**").

DETAILS OF SIGNIFICANT WEALTH MANAGEMENT PRODUCTS

No.	Subscriber	Subscription Date	Bank	Type of Wealth Management Product	Subscription Principal Amount	Date of Maturity	Expected Annualized Yield	Fair Value as of December 31, 2025	Percentage to the Group's Total Assets as of December 31, 2025	Fair Value Gain for the Year Ended December 31, 2025
1.	The Company	June 18, 2025	Bank of Jiangsu	Fixed-income-like product	RMB81.00 million	January 21, 2026	2.75%	RMB82.26 million	5.94%	RMB1.26 million*
2.	The Company	February 21, 2025	Bank of Jiangsu	Fixed-income-like product	RMB120.00 million	February 25, 2026	3.10%	RMB123.13 million	8.89%	RMB3.13 million*
3.	The Company	March 14, 2025	Bank of Jiangsu	Fixed-income-like product	RMB80.00 million	March 20, 2026	3.00%	RMB82.03 million	5.92%	RMB2.03 million*
4.	The Company	November 4, 2024, April 1, 2025 and July 22, 2025	Bank of Hangzhou	Fixed-income-like product	RMB76.00 million	March 20, 2026, July 20, 2026 and November 2, 2026	1.90%	RMB77.89 million	5.62%	RMB1.67 million*

* As the relevant Significant Wealth Management Product had not matured as of December 31, 2025, this figure represents the fair value gains for the year ended December 31, 2025 (instead of the amount of actual interest received).

As at December 31, 2025, the Company's investment portfolio consisted of relatively low-risk fixed-income-like wealth management products provided by licensed banks in the PRC (including the Significant Wealth Management Products), reflecting the Company's relatively prudent investment strategy that balances liquidity and income stability. The funds for these investments were sourced from the Company's own funds prior to the Global Offering, and therefore did not include any proceeds from the Global Offering. For the year ended December 31, 2025, the Company's investments in wealth management products generated an effective annualized return rate of approximately 2.72%.

The Company considers that the Significant Wealth Management Products generate a stable and better return than letting its idle funds earn a nominal interest provided by ordinary bank accounts. For the year ended December 31, 2025, the Significant Wealth Management Products generated an effective annualized return rate of approximately 2.20% to 3.27%. The Company subscribed Significant Wealth Management Products through Bank of Jiangsu and Bank of Hangzhou, which are licensed banks in the PRC. Such Significant Wealth Management Products are classified as R2 (low-to-medium risk, non-principal-guaranteed), and their underlying assets primarily consist of fixed-income products characterized by stable cash flows.

The Company adopts a prudent internal control mechanism for its investment in wealth management products. The Company generally limits its investments in wealth management products to those with risk ratings of R1 (low risk) and R2 (low-to-medium risk), the expected returns of which should exceed the prevailing bank deposit rates. In addition, the Company subscribes wealth management products through licensed banks with relatively high credit ratings, and ensures that its investment in the wealth management products will not affect the ordinary corporate activities and main business of the Group. In terms of approval and oversight mechanisms, the finance department of the Company will conduct preliminary product screening, product due diligence and investment proposal preparation, and all decisions regarding investing in wealth management products must be jointly reviewed by the Finance Director and the Chief Executive Officer of the Company (the "**CEO**"), and approved by the CEO. Any proposed subscription of wealth management products that will trigger disclosure and/or Shareholders' approval requirements under the Listing Rules shall also be reviewed and approved by the Board.

Save as disclosed above, no single investment of the Group accounted for more than 5% of the total assets of the Group as at December 31, 2025 and all other information in the Annual Report remains unchanged.

By order of the Board
Shenzhen Edge Medical Co., Ltd.
(深圳市精鋒醫療科技股份有限公司)
Dr. Wang Jianchen
Chairman of the Board and Executive Director

PRC, November 2, 2026

As at the date of this announcement, the Board comprises Dr. Wang Jianchen, Dr. Gao Yuanqian, and Ms. Wu Mengyuan as executive Directors; Mr. Sheng Li, Mr. Chen Gang, and Mr. Qiu Xiang as non-executive Directors; and Mr. Yang Fan, Mr. Zhang Guoguang and Mr. Lau Ying Kit as independent non-executive Directors.